Web designing in a powerful way of just not an only professions. We have tendency to believe the idea that smart looking .
The Bone Marrow Transplant Center at İnönü University Faculty of Medicine Turgut Özal Medical Center completed its internal organization and received a license from the Ministry of Health in 2010, starting bone marrow transplants. Our center successfully performs autologous, allogeneic, haploidentical, and unrelated bone marrow transplants. In 2014, a total of 67 bone marrow transplants were performed, including 2 haploidentical, 27 allogeneic, and 38 autologous transplants. In 2015, unrelated bone marrow transplants began at our center, with 2 performed in June of that year. For one of these patients, the suitable marrow was brought from Germany, and for the other, it was sourced from the United States, enabling the bone marrow transplant to be carried out at our center.
In 2015, a total of 67 patients underwent stem cell transplants, and in 2016, a total of 74 patients received stem cell transplants. Among these, 25 were allogeneic, 45 were autologous, 5 were unrelated, and 1 was haploidentical. Our mortality rates associated with bone marrow transplants are in line with American and European standards. We are the largest licensed bone marrow transplant center in Turkey, with 40 beds. In 2021, we performed 277 bone marrow transplants, in 2022 a total of 177, and in 2023, 245 bone marrow transplants, making us the hospital with the highest number of stem cell transplants in Turkey. In total, our center has performed over 2,000 bone marrow transplants. Our hospital is equipped with sufficient resources and personnel to conduct all types of bone marrow transplants. İnönü University Turgut Özal Medical Center is one of the leading centers in Turkey for adult bone marrow transplants and continues to be competitive in the field of health tourism.
The Hematology Department is a scientific field primarily focused on the treatment of various blood cancers, including leukemia, lymphoma, myelodysplastic syndromes (MDS), and myeloproliferative disorders. In addition to these cancers, our department also manages the diagnosis and treatment of various conditions such as bleeding and coagulation disorders, anemias, and bone marrow dysfunctions.
Currently, while chemotherapy is the main treatment option for leukemia, lymphoma, MDS, and myeloproliferative diseases, a significant portion of these patients require bone marrow transplantation to completely eliminate the disease from the body (curative treatment). As is known, various types of bone marrow transplants are performed, including autologous, allogeneic, haploidentical, and unrelated transplants. Each of these transplants has its own successes and risks. Factors such as the patient’s age, the nature of the disease, and the availability of suitable marrow play a role in the selection of the transplant type by hematologists.
In our center, patients undergoing treatment and monitoring are evaluated individually to determine whether a transplant is necessary. If a transplant is needed, the type of transplant to be performed is decided by the Bone Marrow Transplant Council within the regulations of the Ministry of Health.
Patients receive 4 cycles (months) of treatment with Bortezomib, cyclophosphamide, and dexamethasone before undergoing autologous stem cell transplantation (ASCT). Each cycle lasts 21 days, and after the patient is discharged, they rest for one week before moving on to the next cycle. Each cycle totals 1 month. For suitable patients, treatments on days 1, 4, 8, and 11 can be administered on an outpatient basis. Patients who are not suitable must receive all treatments inpatient.
If the patient is in remission after 4 months of treatment, autologous stem cell transplantation is performed. Stem cell collection (mobilization) takes an average of 15 days. The conditioning regimen involves the use of Melphalan for ASCT. Patients are typically discharged 15-21 days after the ASCT. The treatment for a patient diagnosed with Multiple Myeloma is generally completed about 5-6 months after diagnosis.
Patients receive one cycle of remission-induction treatment (3+7). The average hospital stay is 1 month. Following this, they undergo another cycle of consolidation treatment with high-dose cytarabine, which also requires an average stay of 1 month. Patients are discharged after each cycle for 1 week to rest.
If a patient is in remission and has a fully matched sibling donor (10/10), a bone marrow transplant is performed. If there is no fully matched sibling donor, the transplant is carried out using an unrelated or haploidentical (partially matched) donor. This treatment also lasts about 1 month. The treatment for an AML patient is typically completed approximately 3-4 months after diagnosis. Patients are monitored weekly for the first 100 days post-transplant, for a total of 6 months.
Patients receive 2 cycles of treatment according to their performance status, using regimens such as CALGB or Hyper CVAD. These treatments typically last about 2 months. Patients are discharged for 1 week to rest after each cycle.
If a patient is in remission and has a fully matched sibling donor (10/10), a bone marrow transplant is performed. If there is no fully matched sibling donor, the transplant is carried out using an unrelated or haploidentical (partially matched) donor. This treatment also lasts about 1 month. The treatment for an ALL patient is generally completed approximately 3-4 months after diagnosis. Patients are monitored weekly for the first 100 days post-transplant, totaling 6 months of follow-up.
Patients receive 4 cycles of CODOX-M/IVAC chemotherapy. Each cycle lasts 21 days. After each cycle, patients are discharged and allowed to rest for 1 week. This treatment typically lasts about 4 months. Stem cell collection (mobilization) takes an average of 15 days. The conditioning regimen involves using the Bu-CY-Eto regimen for autologous stem cell transplantation (ASCT). After the ASCT, patients are usually discharged 15-21 days later. The treatment for a patient diagnosed with Burkitt Lymphoma is generally completed approximately 5-6 months after diagnosis.
Patients receive 2 cycles of the DHAP regimen. After each cycle, patients are discharged and allowed to rest for 1 week. This treatment typically lasts about 2 months. In our patients, mobilization is performed at the end of the DHAP regimen, so additional mobilization regimens are not necessary. The conditioning regimen involves using the Bu-CY-Eto regimen for autologous stem cell transplantation (ASCT). After the ASCT, patients are usually discharged 15-21 days later. The treatment for a patient diagnosed with relapsed lymphoma is generally completed approximately 3 months after diagnosis.
In our center, bone marrow transplants are also performed for patients with Chronic Myelogenous Leukemia, Aplastic Anemia, Myelodysplastic Syndromes, Thalassemia, solid tumors, and Myelofibrosis who do not respond to drug treatment.